Platinum-Sensitive Relapsed Ovarian Cancer Archives

AstraZeneca and Merck’s Combo Therapy Flunks Late-Stage Ovarian Cancer Trial

BRCA mutation, Business, Clinical Trials, Collaborations, Combination Therapies, DNA Damage Response (DDR), National Cancer Institute, NRG Oncology, PARP Inhibitors, Platinum-Sensitive Relapsed Ovarian Cancer, R&D, Vascular Endothelial Growth Factor (VEGF) Inhibitors

AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.

March 12, 2020/by BioSpace

AstraZeneca-Merck's Lynparza wins approval in China for ovarian cancer treatment

Approvals, China Food and Drug Administration, FDA/Regulatory, Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca Plc and Merck & Co. Inc.’s Lynparza won approval in China as a first-line treatment for a form of ovarian cancer.

December 5, 2019/by Reuters Health